54TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 AVENACY 24/7 BIOPHARMA had the opportunity to speak with Jeffrey Yordon, CEO and co-founder of Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, at DCAT Week 2025. In this interview, Yordon discussed launching his latest company, how Avenacy aims to separate itself from competitors, and what it takes to navigate the tumultuous nature of the current biopharma business environment. Launching Avenacy Avenacy was founded in October 2023 by Yordon and long-time business partner Kam Phulwani. Notably, Avenacy is not the first, second, or even fifth company that Yordon has founded; he has a long history of founding specialty pharma companies, building them up, and selling them to outside investors. Notable companies he founded include American Pharmaceutical Partners, which Fresenius Kabi purchased for approximately $3.7 billion in 2008, and Sagent Pharmaceuticals, which NichiIko Pharmaceutical acquired in a deal valued at $736 million in 2016. “You know, I like to say maybe I was lucky the first time, the second time,” says Yordon. “You’re not lucky seven times. People would invest in me because I always did what I said I was going to do.” Through a rigorous and optimized selection process, Avenacy is building out a portfolio of high-quality FDA approved products capable of delivering sustainable growth while providing reliability, safety, and convenience for customers. The Company has announced the launch of 20 products since inception in October 2023. Navigating the generic market According to Yordon, in many ways Avenacy is following the same model that he began implementing in his companies around the turn of the century. Because the FDA requires dedicated facilities for certain types of pharmaceuticals, it is very difficult to personally own and operate the manufacturing facilities needed to sustain a wide catalog of products. “So I said what we’re going to do is we’re going to find partners that have pristine FDA-approved facilities and pristine development facilities, and they’re going to be our partners,” says Yordon. “They’ll develop and manufacture the products. We’ll tell them which products to develop.
RkJQdWJsaXNoZXIy MjY2OTA4MA==